Dalotuzumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade

Introduction

Dalotuzumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R) and is used in research settings. In this article, we will discuss the structure, activity, and applications of this biosimilar.

Structure of Dalotuzumab Biosimilar

Dalotuzumab Biosimilar is a recombinant humanized monoclonal antibody that is derived from a mouse antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the IGF1R receptor, while the constant region determines the antibody’s effector functions.

Activity of Dalotuzumab Biosimilar

Dalotuzumab Biosimilar works by binding to the IGF1R receptor on the surface of cells. This receptor is involved in cell growth, proliferation, and survival, making it a promising therapeutic target in cancer and other diseases. By binding to the IGF1R receptor, Dalotuzumab Biosimilar blocks the binding of insulin-like growth factor 1 (IGF1), a hormone that activates the receptor. This leads to inhibition of downstream signaling pathways that promote cell growth and survival.

Applications of Dalotuzumab Biosimilar

Dalotuzumab Biosimilar is primarily used in research settings to study the role of IGF1R in various diseases. It has been extensively studied in cancer, as the IGF1R pathway is often dysregulated in cancer cells, promoting their growth and survival. Dalotuzumab Biosimilar has shown promising results in preclinical studies as a potential treatment for various types of cancer, including breast, lung, and pancreatic cancer.

In addition to cancer, Dalotuzumab Biosimilar has also been investigated in other diseases, such as diabetes and growth disorders. In diabetes, the IGF1R pathway plays a role in insulin resistance, and Dalotuzumab Biosimilar has shown potential in improving insulin sensitivity in preclinical studies. In growth disorders, IGF1R is involved in regulating growth hormone signaling, and Dalotuzumab Biosimilar has been studied as a potential treatment for growth hormone deficiency.

Conclusion

In summary, Dalotuzumab Biosimilar is a promising monoclonal antibody that targets the IGF1R receptor and has potential applications in various diseases, particularly cancer. Its structure and activity allow for specific binding to the IGF1R receptor, leading to inhibition of downstream signaling pathways involved in cell growth and survival. As research in this field continues, Dalotuzumab Biosimilar may prove to be a valuable tool in understanding and treating diseases related to IGF1R dysregulation.